EC Microbiology

Although the relationship between both the inflammatory process and insulin resistance (IR) in obesity (O), mediated by the intestinal microbiota, is currently unquestionable, it is essential to carry out a review to determine as close as possible, if it is enough with the fecal microbiota transplant (Microbiota modulator), to improve the metabolic syndrome (MetS).

MetS is a group of processes that increase the risk of diseases such as coronary artery disease, type 2 diabetes mellitus, stroke and others. And it usually manifests: arterial hypertension, increased blood glucose, increased LDL and triglycerides. In addition to O, Polycystic Ovary Syndrome, as well as increased abdominal diameter. There is adiposity, genetic susceptibility, endothelial dysfunction and hypercoagulability and chronic stress. Non-alcoholic fatty liver disease and lipodystrophy associated with protease inhibitors should be included in all cases. It is very frequent in the United States of America, presenting the process in one of every 3 adults. Being able to prevent with simple measures, although very quickly abandoned. The patient is usually sedentary and eats an atherogenic diet.

Due to the above, we consider that to all the known measures to combat MetS, others should be added to improve this frequent pathology. Among these procedures, the fecal microbiota transplant (FMT) stands out.

In this article we address all the measures that are in the medical arsenal, including the central theme that is the FMT.

Keywords: Metabolic Syndrome (MetS); Fecal Microbiota Transplantation (FMT); Insulin Resistance (IR); Obesity (O)

1. Metabolic Syndrome. What is Metabolic Syndrome? NIH. National Heart, Lung and Blood Institute. Official websites use (2020).
2. Julie Rask Larsen., et al. “The pharmacological management of metabolic syndrome”. Expert Review of Clinical Pharmacology4 (2108): 397-410.
3. Arati Wagh and Neil J Stone. “Treatment of metabolic syndrome”. Expert Review of Cardiovascular Therapy2 (2004): 213-228.
4. Jaspinder Kaur. "A Comprehensive Review on Metabolic Syndrome”. Cardiology Research and Practice (2014).
5. Shamsuddin SA., et al. “Stem cells as a potential therapy in managing various disorders of metabolic syndrome: a systematic review”. American Journal of Translational Research11 (2021): 12217-12227.
6. Tang QR., et al. “Evaluation of the Clinical Efficacy of Stem Cell Transplantation in the Treatment of Spinal Cord Injury: A Systematic Review and Meta-analysis”. Cell Transplant 30 (2021): 9636897211067804.
7. Matsushita K. “Mesenchymal Stem Cells and Metabolic Syndrome: Current Understanding and Potential Clinical Implications”. Stem Cells International (2016): 2892840.
8. Runkel N and Brydniak R. “Surgical Treatment of Metabolic Syndrome”. Visceral Medicine5 (2016): 352-356.
9. Ji Y., et al. “Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms”. Biomolecules11 (2021): 1582.
10. Malnick SDH., et al. “Treating the Metabolic Syndrome by Fecal Transplantation. Current Status”. Biology5 (2021): 447.
11. Quaranta G., et al. “Fecal Microbiota Transplantation: A Potential Tool for Treatment of Human Female Reproductive Tract Diseases”. Frontiers in Immunology 10 (2019): 2653.
12. Marcella C., et al. “Systematic review: the global incidence of faecal microbiota transplantation-related Adverse events from 2000 to 2020”. Alimentary Pharmacology and Therapeutics1 (2021): 33-42.
13. Sachs J. “Complications of Stem Cell Transplants”. Medically Reviewed by Arnold Wax, WebMD (2012).
14. Waszczuk-Gajda A., et al. “Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study”. Journal of Clinical Medicine12 (2022): 3541.
15. Livingston EH. “Complications of Bariatric Surgery”. Surgical Clinics4 (2005): 853-868.
16. Zheng L., et al. “Fecal microbiota transplantation in the metabolic diseases: Current Status and perspectives”. World Journal of Gastroenterology23 (2022): 2546-2560.
17. Ragbourne SC and Crook MA. “Metabolic Syndrome in Long-Term Survivors of Hematopoietic Stem-Cell Transplantation”. Clinical Lymphoma Myeloma and Leukemia6 (2017): 340-346.
18. Batsis JA., et al. “Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study”. Mayo Clinic Proceedings8 (2008): 897-907.
19. Marotz CA and Zarrinpar A. “Treating Obesity and Metabolic Syndrome with Fecal Microbiota Transplantation”. Yale Journal of Biology and Medicine3 (2016): 383-388.
20. Baldi S., et al. “Microbiota shaping - the effects of probiotics, prebiotics, and Fecal microbiota transplant on cognitive functions: A systematic review”. World Journal of Gastroenterology39 (2021): 6715-6732.
21. Lahtinen P., et al. “Effectiveness of Fecal Microbiota Transplantation for Weight Loss in Patients with Obesity Undergoing Bariatric Surgery. A Randomized Clinical Trial. Gastroenterology and Hepatology”. JAMA Network Open12 (2022): e2247226.
22. Al-Yassir F., et al. “Modulation of Stem Cell Progeny by Probiotics during Regeneration of Gastric Mucosal Erosions”. Biology7 (2021): 596.
23. Fleishman CIPA. “International Probiotics Association”. Bariatric Surgery. A Role for Probiotics? (2022).
24. Quaranta G., et al. “Fecal Microbiota Transplantation and Other Gut Microbiota Manipulation Strategies”. Microorganisms12 (2022): 2424.
25. Andermann TM., et al. “Microbiota Manipulation with Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation”. Current Hematologic Malignancy Reports1 (2016): 19-28.
26. Nowicki KN and Pories WJ. “Bacteria with potential: Improving outcomes through probiotic use following Roux-En-Y gastric bypass”. Clinical Obesity1 (2023): e12552.
27. Tan Q., et al. “Probiotics, prebiotics, synbiotics, and fecal microbiota transplantation in the treatment of behavioral symptoms of autism spectrum disorder: A systematic review”. Autism Research9 (2021): 1820-1836.